Noriomi Matsumura

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/4556053/noriomi-matsumura-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

72 2,224 23 46 g-index

94 2,903 4.7 4.95 ext. papers ext. citations avg, IF L-index

| # | Paper | IF | Citations |
|----|---|------|-----------|
| 72 | Oncologic outcomes in elderly patients who underwent hysterectomy for endometrial cancer: a multi-institutional survey in Kinki District, Japan <i>International Journal of Clinical Oncology</i> , 2022 , 1 | 4.2 | Ο |
| 71 | Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs <i>International Journal of Clinical Oncology</i> , 2022 , | 4.2 | 2 |
| 70 | The roles and limitations of bevacizumab in the treatment of ovarian cancer <i>International Journal of Clinical Oncology</i> , 2022 , 1 | 4.2 | 1 |
| 69 | B7-H3 suppresses anti-tumor immunity via the CCL2-CCR2-M2 macrophage axis and contributes to ovarian cancer progression. <i>Cancer Immunology Research</i> , 2021 , | 12.5 | 3 |
| 68 | Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2021 , 27, 4669-4679 | 12.9 | 28 |
| 67 | Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma. <i>Modern Pathology</i> , 2021 , 34, 2071-2079 | 9.8 | 1 |
| 66 | Targeting Dormant Ovarian Cancer Cells and in an Mouse Model of Platinum Resistance. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 85-95 | 6.1 | 1 |
| 65 | A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review. <i>Oncologist</i> , 2021 , 26, 356-361 | 5.7 | 3 |
| 64 | Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. <i>JCO Precision Oncology</i> , 2021 , 5, | 3.6 | 1 |
| 63 | PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma. <i>Cancer Science</i> , 2021 , 112, 4627-4640 | 6.9 | 1 |
| 62 | The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. <i>Journal of Gynecologic Oncology</i> , 2021 , 32, e49 | 4 | 5 |
| 61 | Characterization of patients that can continue conservative treatment for adenomyosis <i>BMC Womens Health</i> , 2021 , 21, 431 | 2.9 | |
| 60 | Superparamagnetic iron oxide as a tracer for sentinel lymph node detection in uterine cancer: a pilot study. <i>Scientific Reports</i> , 2020 , 10, 7945 | 4.9 | 4 |
| 59 | Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy. <i>Cancers</i> , 2020 , 12, | 6.6 | 13 |
| 58 | A case of left renal atrophy following the development of an infected giant retroperitoneal chylous cyst after laparoscopic para-aortic lymphadenectomy for endometrial cancer. <i>International Cancer Conference Journal</i> , 2020 , 9, 203-206 | 0.9 | |
| 57 | Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. <i>Scientific Reports</i> , 2020 , 10, 2757 | 4.9 | 55 |
| 56 | Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. <i>British Journal of Cancer</i> , 2020 , 122, 778-788 | 8.7 | 32 |

(2018-2020)

| 55 | Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis. <i>European Journal of Surgical Oncology</i> , 2020 , 46, 868-875 | 3.6 | 10 |
|----|--|------|-----|
| 54 | Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. <i>Gynecologic Oncology</i> , 2020 , 156, 415-422 | 4.9 | 13 |
| 53 | Low-Grade Endometrial Stromal Sarcoma with a Nodule-in-Nodule Appearance in Preoperative Magnetic Resonance Images. <i>Case Reports in Obstetrics and Gynecology</i> , 2020 , 2020, 8973262 | 0.8 | 0 |
| 52 | Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts. <i>International Journal of Clinical Oncology</i> , 2020 , 25, 51-58 | 4.2 | 15 |
| 51 | Placental sonic hedgehog pathway regulates foetal growth via insulin-like growth factor axis in preeclampsia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , | 5.6 | 7 |
| 50 | Association between preterm delivery and bacterial vaginosis with or without treatment. <i>Scientific Reports</i> , 2019 , 9, 509 | 4.9 | 28 |
| 49 | The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1). Gynecologic Oncology, 2019, 153, 312-319 | 4.9 | 12 |
| 48 | Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. <i>Medical Molecular Morphology</i> , 2019 , 52, 52-59 | 2.3 | 12 |
| 47 | Severe fatty liver of pregnancy requiring an extremely large amount of blood transfusion, surgery and transarterial embolization: A case report. <i>Case Reports in Womens Health</i> , 2019 , 23, e00130 | 1.6 | 1 |
| 46 | Acquisition of a side population fraction augments malignant phenotype in ovarian cancer. <i>Scientific Reports</i> , 2019 , 9, 14215 | 4.9 | 10 |
| 45 | Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor. <i>Healthcare (Switzerland)</i> , 2019 , 7, | 3.4 | 1 |
| 44 | Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma using Magnetic Resonance Images: A Literature Review. <i>Healthcare (Switzerland)</i> , 2019 , 7, | 3.4 | 10 |
| 43 | VISTA expressed in tumour cells regulates T cell function. <i>British Journal of Cancer</i> , 2019 , 120, 115-127 | 8.7 | 79 |
| 42 | Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. <i>Nature Communications</i> , 2018 , 9, 1685 | 17.4 | 117 |
| 41 | Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status. <i>International Journal of Clinical Oncology</i> , 2018 , 23, 698-706 | 4.2 | 6 |
| 40 | Impaired Wnt5a signaling in extravillous trophoblasts: Relevance to poor placentation in early gestation and subsequent preeclampsia. <i>Pregnancy Hypertension</i> , 2018 , 13, 225-234 | 2.6 | 9 |
| 39 | The effect of the type of dietary protein on the development of ovarian cancer. <i>Oncotarget</i> , 2018 , 9, 23987-23999 | 3.3 | 5 |
| 38 | Two cases of recurrent uterine cervical cancer with arterio-enteric fistula treated by femoro-femoral artery bypass in hybrid operation room. <i>International Cancer Conference Journal</i> , 2018 , 7, 26-29 | 0.9 | 1 |

| 37 | Longitudinal changes in magnetic resonance imaging of malignant and borderline tumors associated with ovarian endometriotic cyst comparing with endometriotic cysts without arising malignancy. <i>European Journal of Radiology</i> , 2018 , 105, 175-181 | 4.7 | 5 |
|----|---|--------------------|-----|
| 36 | Clear Cell Carcinoma of the Ovary 2017 , 550-556 | | |
| 35 | Pneumonia in Non-HIV Pregnant Women Receiving Chemotherapy for Malignant Lymphoma: Two Case Reports. <i>Case Reports in Obstetrics and Gynecology</i> , 2017 , 2017, 1073146 | 0.8 | 1 |
| 34 | Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. <i>Journal of Gynecologic Oncology</i> , 2017 , 28, e54 | 4 | 12 |
| 33 | Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum. <i>BMC Cancer</i> , 2017 , 17, 580 | 4.8 | 8 |
| 32 | Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. <i>Journal of Gynecologic Oncology</i> , 2017 , 28, e62 | 4 | 4 |
| 31 | Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy. <i>Medical Science Monitor</i> , 2017 , 23, 826-833 | 3.2 | 2 |
| 30 | Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. <i>American Journal of Pathology</i> , 2017 , 187, 2246-2 | 2 5 8 | 66 |
| 29 | Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 587 | -5 59 9 | 148 |
| 28 | Adult granulosa cell tumors of the ovary: a retrospective study of 30 cases with respect to the expression of steroid synthesis enzymes. <i>Journal of Gynecologic Oncology</i> , 2017 , 28, e31 | 4 | 7 |
| 27 | Subtypes of Ovarian Cancer and Ovarian Cancer Screening. <i>Diagnostics</i> , 2017 , 7, | 3.8 | 48 |
| 26 | Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer. Oncotarget, 2017 , 8, 106866-106875 | 3.3 | 22 |
| 25 | Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer. <i>Journal of International Medical Research</i> , 2016 , 44, 346-56 | 1.4 | 4 |
| 24 | Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. <i>Gynecologic Oncology</i> , 2016 , 141, 49-56 | 4.9 | 24 |
| 23 | Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. <i>American Journal of Pathology</i> , 2016 , 186, 1103-13 | 5.8 | 52 |
| 22 | Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma. <i>Oncotarget</i> , 2016 , 7, 54758-54770 | 3.3 | 20 |
| 21 | Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. <i>Oncotarget</i> , 2016 , 7, 47620-47636 | 3.3 | 21 |
| 20 | Clinical Efficacy of Ovarian Cancer Screening. <i>Journal of Cancer</i> , 2016 , 7, 1311-6 | 4.5 | 8 |

(2006-2016)

| 19 | Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016 , 35, e247 | 7-37 | 9 |
|----|---|------|-----|
| 18 | Groin lymph node detection and sentinel lymph node biopsy in vulvar cancer. <i>Journal of Gynecologic Oncology</i> , 2016 , 27, e57 | 4 | 9 |
| 17 | Dual Faces of IFNIIn Cancer Progression: A Role of PD-L1 Induction in the Determination of Proand Antitumor Immunity. <i>Clinical Cancer Research</i> , 2016 , 22, 2329-34 | 12.9 | 238 |
| 16 | Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. <i>Cancer Research</i> , 2015 , 75, 5034-45 | 10.1 | 318 |
| 15 | Hepatocyte nuclear factor-1[[HNF-1]] promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. <i>Molecular Carcinogenesis</i> , 2015 , 54, 35-49 | 5 | 45 |
| 14 | Subendometrial enhancement and peritumoral enhancement for assessing endometrial cancer on dynamic contrast enhanced MR imaging. <i>European Journal of Radiology</i> , 2015 , 84, 581-9 | 4.7 | 19 |
| 13 | Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. <i>Cancer Biology and Therapy</i> , 2014 , 15, 22-5 | 4.6 | 11 |
| 12 | Recent concepts of ovarian carcinogenesis: type I and type II. <i>BioMed Research International</i> , 2014 , 2014, 934261 | 3 | 119 |
| 11 | Epigenetic and genetic dispositions of ovarian carcinomas. <i>Oncoscience</i> , 2014 , 1, 574-9 | 0.8 | 11 |
| 10 | Laparoscopic pelvic lymphadenectomy in patients with early-stage endometrial cancer. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2013 , 29, 291-296 | Ο | |
| 9 | PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. <i>Clinical Cancer Research</i> , 2013 , 19, 1363-74 | 12.9 | 151 |
| 8 | The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. <i>International Journal of Cancer</i> , 2012 , 130, 20-8 | 7.5 | 47 |
| 7 | Ovarian clear cell carcinoma as a stress-responsive cancer: influence of the microenvironment on the carcinogenesis and cancer phenotype. <i>Cancer Letters</i> , 2011 , 310, 129-33 | 9.9 | 32 |
| 6 | Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. <i>Cancer Science</i> , 2010 , 101, 2658-63 | 6.9 | 29 |
| 5 | Activated local immunity by CC chemokine ligand 19-transduced embryonic endothelial progenitor cells suppresses metastasis of murine ovarian cancer. <i>Stem Cells</i> , 2010 , 28, 164-73 | 5.8 | 35 |
| 4 | Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. <i>International Journal of Clinical Oncology</i> , 2009 , 14, 383-91 | 4.2 | 118 |
| 3 | Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment. <i>Oncology Reports</i> , 2008 , 19, 505-15 | 3.5 | 6 |
| 2 | Oncogenic property of acrogranin in human uterine leiomyosarcoma: direct evidence of genetic contribution in in vivo tumorigenesis. <i>Clinical Cancer Research</i> , 2006 , 12, 1402-11 | 12.9 | 55 |

Changes in the serum levels of human chorionic gonadotropin and the pulsatility index of uterine arteries during conservative management of retained adherent placenta. *Journal of Obstetrics and Gynaecology Research*, **2000**, 26, 81-7

29